Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EEF1A1P22 is a **processed pseudogene** of the eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) gene. Pseudogenes like EEF1A1P22 arise from duplication or retrotransposition events and do not encode functional proteins. The EEF1A1 gene itself encodes a key factor in translation elongation by delivering aminoacylated tRNAs to the ribosome, but EEF1A1P22 does not produce this or any related protein. Its role, if any, in human biology remains primarily uncharacterized, with no evidence supporting it as a therapeutic target or as a direct biomarker in disease[1][3]. The function and disease relevance of most EEF1A1 pseudogenes, including EEF1A1P22, are currently unknown; they may potentially regulate their parental gene or participate in other non-protein-coding regulatory mechanisms, but this remains speculative and is not experimentally validated[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation elongation factor 1 alpha 1 pseudogene 22 (EEF1A1P22).